Numbers can lie -- yet they're the best first step in determining whether a stock is a buy. In this series, we use some carefully chosen metrics to size up a stock's true value based on the following clues:
Let's see what those numbers can tell us about how expensive or cheap Bristol-Myers Squibb (NYSE: BMY) might be.
The current price multiples
First, we'll look at most investors' favorite metric: the price-to-earnings ratio. It divides the company's share price by its earnings per share (EPS). The lower the P/E, the better.
Then we'll take things up a notch with a more advanced metric: enterprise value to unlevered free cash flow. This tool divides the company's enterprise value (basically, its market cap plus its debt, minus its cash) by its unlevered free cash flow (its free cash flow, adding back the interest payments on its debt). As with the P/E, the lower this number is, the better.
Analysts argue about which is more important -- earnings or cash flow. Who cares? A good buy ideally has low multiples on both.
Bristol-Myers has a P/E ratio of 4.2 and an EV/FCF ratio of 11.2 over the trailing 12 months. If we stretch and compare current valuations with the five-year averages for earnings and free cash flow, we see that Bristol-Myers has a P/E ratio of 9.8 and a five-year EV/FCF ratio of 16.0.
A one-year ratio of less than 10 for both metrics is ideal. For a five-year metric, less than 20 is ideal.
Bristol-Myers has a mixed performance in hitting the ideal targets, but let's see how it stacks up against some of its competitors and industry mates.
Company |
1-Year P/E |
1-Year EV/FCF |
5-Year P/E |
5-Year EV/FCF |
---|---|---|---|---|
Bristol-Myers Squibb |
4.2 |
11.2 |
9.8 |
16.0 |
Abbott Laboratories (NYSE:ABT) |
15.6 |
11.6 |
18.3 |
15.8 |
Merck (NYSE: MRK) |
14.1 |
14.4 |
17.9 |
21.3 |
Pfizer (NYSE: PFE) |
22.2 |
16.2 |
13.0 |
11.3 |
Source: Capital IQ, a division of Standard & Poor's; NM = not meaningful.
Numerically, we've seen how Williams-Sonoma‘s valuation rates on both an absolute and relative basis. Next, let's examine …
The consistency of past earnings and cash flow
An ideal company will be consistently strong in its earnings and cash-flow generation.
In the past five years, Bristol-Myers' net income margin has ranged from 11.8% to 54.8%. In that same time frame, unlevered free cash flow margin has ranged from 9.1% to 19.8%.
How do those figures compare with those of the company's peers? See for yourself:
In addition, over the past five years, Bristol-Myers has tallied up five years of positive earnings and five years of positive free cash flow.
Next, let's figure out …
How much growth we can expect
Analysts tend to comically overstate their five-year growth estimates. If you accept them at face value, you will overpay for stocks. But even though you should definitely take the analysts' prognostications with a grain of salt, they can still provide a useful starting point when compared with similar numbers from a company's closest rivals.
Let's start by seeing what this company's done over the past five years. In that time period, Bristol-Myers has put up past EPS growth rates of 7.0%. Meanwhile, Wall Street's analysts expect future growth rates of 3.9%.
Here's how Bristol-Myers compares with its peers for trailing five-year growth:
And here's how it measures up with regard to the growth analysts expect over the next five years:
The bottom line
The pile of numbers we've plowed through has shown us how cheap shares of Bristol-Myers are trading, how consistent its performance has been, and what kind of growth profile it has -- both on an absolute and a relative basis.
The more consistent a company's performance has been and the more growth we can expect, the more we should be willing to pay. We've gone well beyond looking at a 4.2 P/E ratio, which, as it turns out, is largely the result of a one-time gain. Much as the real estate game is all “location, location, location,” the name of the game in big pharma is “pipeline, pipeline, pipeline.”
But if you find Bristol-Myers' numbers compelling, don't stop here. Continue your due-diligence process (beginning with assessing Bristol-Myers' pipeline) until you're confident that the initial numbers aren't lying to you.
© 2010 UCLICK L.L.C.